NHS Dudley Health Economy Medicines Formulary
Home > 8 Malignant disease and immunosuppression > 8.1 Cytotoxic drugs > 8.1.3 Antimetabolites > Myelodysplastic syndromes - azacitidine - NICE TAG TA218

Myelodysplastic syndromes - azacitidine - NICE TAG TA218

1.1 Azacitidine is recommended as a treatment option for adults who are not eligible for haematopoietic stem cell transplantation and have:

  • intermediate-2 and high-risk myelodysplastic syndromes according to the International Prognostic Scoring System (IPSS) or

  • chronic myelomonocytic leukaemia with 10–29% marrow blasts without myeloproliferative disorder or

  • acute myeloid leukaemia with 20–30% blasts and multilineage dysplasia, according to the World Health Organization classification and

  • if the manufacturer provides azacitidine with the discount agreed as part of the patient access scheme.

 

https://www.nice.org.uk/guidance/TA218

Site by Devopa
© Copyright 2019 NHS. All rights reserved.